Expands Branded Product Portfolio and Develops New Markets for Gastrointestinal and Respiratory Products

HONG KONG, CHINA - Media OutReach - 31 October 2019 - Jacobson PharmaCorporation Limited ("Jacobson Pharma" or the  "Company"; Stock Code: 2633), a leading companyengaging in the research, development, production, marketing and sale ofgeneric drugs and proprietary medicines, announced today that its wholly-owned subsidiary Smiley Sun Limited ("Smiley") has signed ajoint venture agreement (the "JV Agreement") with Kin Fung Weisen-UCompany Limited ("Kin Fung Weisen-U") to set up a new company (the "Joint Venture")which will be 50%-owned respectively by Smiley and Kin Fung Weisen-U.

The Joint Venturewill distribute and sell certain products of Kin Fung Weisen-U, including thewell-recognised gastrointestinal drug "Weisen-U" (「胃仙-U」) and the popularnasal spray brand "Flucur Nebuliser" (「呼佳噴霧劑」) to new markets in the Asia Pacific region. It willcreate an expanded proprietary medicine platform for the Group in support ofits regional market development strategy.

The Joint Venturewill also explore and develop respective product line extensions for Weisen-U (「胃仙-U」) and Po ChaiPills (「保濟丸」). Furthermore, it willexplore and conduct businesses relating to the supply and distribution ofnon-prescription drugs as well as food/health supplements of the gastrointestinaland respiratory categories in markets worldwide. In particular, the Joint Venturewill have the first right over Smiley and Kin Fung Weisen-U to acquire brands of gastrointestinal and respiratory drugs, andfood/health supplements. The Joint Venture will allow the Group to strengthenpresence and penetration in the OTC market segment.

With Kin Fung Weisen-U being along-standing reputable player in the pharmaceutical industry, Jacobson Pharma believesthe Joint Venture will give the Company a sound strategic leverage to broadenits portfolio of gastrointestinal and respiratory drugs, food/healthsupplements and also to speed up expansion in the Asia Pacific market.

About Jacobson Pharma Corporation Limited (雅各臣科研製藥有限公司；Stock Code: 2633)

Jacobson Pharma is the largest generic drug company in Hong Kong withover 30% share of the total generic drug market. The Group's proprietarymedicines, notably being Po Chai Pills (「保濟丸」), Ho ChaiKung Tji Thung San (「何濟公止痛退熱散」), Contractubex Scar Gel (「秀碧除疤膏」) , Flying Eagle Wood Lok Medicated Oil (「飛鷹活絡油」), Tong Tai Chung Woodlok Oil (「唐太宗活絡油」), Doan's Ointment (「兜安氏藥膏」), Saplingtan (「十靈丹」), Shiling Oil (「十靈油」) and Col-gan Tablet (「傷風克」) have been widely recognised by the market.The Group also enriches its portfolio through in-house development or in-licensingof high value-added products covering sterile injections, oncology products,combination drugs, specialty medicines, as well as orphan drugs andbiosimilars. To support its fast growing business, the Group is currentlyoperating business offices established in China, Macau, Taiwan, Singapore andCambodia apart from Hong Kong, giving it a regional market platform for tappingthe high growing market potential in the Asia Pacific and Greater Chinaregions. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1June 2017. For more details about Jacobson Pharma, please visit the Group'swebsite: https://www.jacobsonpharma.com

About Kin Fung Weisen-U Company Limited

Kin Fung Weisen-U was incorporated in Hong Kong in 1960s and is principallyengaged in the development of gastrointestinal and respiratory pharmaceuticaldrugs. Kin Fung Weisen-U is the brand owner and sole agent of Weisen-U (「胃仙-U」) in Hong Kong, Macau and the PRC. Starting from January 2019,Jean-Marie Pharmacal Co. Ltd., a wholly-owned drugs manufacturing subsidiary ofJacobson Pharma Corporation Limited, whereas its production facilities havebeen PIC/S (Pharmaceutical Inspection Co-operation Scheme) GMP accredited, has becomethe contract manufacturer of Weisen-U (「胃仙-U」) for Kin Fung Weisen-U.